BidaskClub upgraded shares of Meridian Bioscience (NASDAQ:VIVO) from a hold rating to a buy rating in a research report sent to investors on Thursday, May 31st.

Separately, Zacks Investment Research raised shares of Meridian Bioscience from a hold rating to a buy rating and set a $17.00 target price on the stock in a research note on Wednesday, March 21st.

Meridian Bioscience traded up $0.25, reaching $16.10, during mid-day trading on Thursday, MarketBeat.com reports. The stock had a trading volume of 178,900 shares, compared to its average volume of 271,366. The stock has a market capitalization of $658.45 million, a price-to-earnings ratio of 23.73 and a beta of 0.96. The company has a debt-to-equity ratio of 0.27, a current ratio of 5.41 and a quick ratio of 3.71. Meridian Bioscience has a 12 month low of $13.35 and a 12 month high of $16.45.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings data on Thursday, April 26th. The company reported $0.21 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.21. The business had revenue of $56.45 million for the quarter, compared to analysts’ expectations of $55.00 million. Meridian Bioscience had a net margin of 8.42% and a return on equity of 16.66%. The firm’s quarterly revenue was up 4.3% compared to the same quarter last year. During the same period last year, the firm posted $0.22 earnings per share. analysts anticipate that Meridian Bioscience will post 0.71 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 17th. Stockholders of record on Monday, May 7th were issued a dividend of $0.125 per share. The ex-dividend date of this dividend was Friday, May 4th. This represents a $0.50 dividend on an annualized basis and a dividend yield of 3.11%. Meridian Bioscience’s dividend payout ratio (DPR) is presently 74.63%.

Several large investors have recently modified their holdings of VIVO. Schwab Charles Investment Management Inc. lifted its holdings in shares of Meridian Bioscience by 12.4% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 471,456 shares of the company’s stock worth $6,601,000 after purchasing an additional 51,976 shares during the period. Bessemer Group Inc. acquired a new position in shares of Meridian Bioscience during the fourth quarter worth $270,000. Algert Global LLC acquired a new position in shares of Meridian Bioscience during the fourth quarter worth $301,000. Alambic Investment Management L.P. lifted its holdings in shares of Meridian Bioscience by 32.3% during the fourth quarter. Alambic Investment Management L.P. now owns 129,300 shares of the company’s stock worth $1,810,000 after purchasing an additional 31,600 shares during the period. Finally, Gabelli Funds LLC lifted its holdings in shares of Meridian Bioscience by 2.0% during the fourth quarter. Gabelli Funds LLC now owns 208,000 shares of the company’s stock worth $2,912,000 after purchasing an additional 4,000 shares during the period. Institutional investors own 87.19% of the company’s stock.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments.

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.